EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3425-3429

  Lu, Ming ^a   Miller, Kathy D ^b   Gokmen Polar, Yesim ^b   Jeng, Meei Huey ^b   Kinch, Michael S ^c  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHA2 RECEPTOR TYROSINE KINASE; ESTROGEN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EA2; MONOCLONAL ANTIBODY EPHA2; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER GROWTH; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TARGETING;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENES, REPORTER; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, EPHA2; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; STRESS; TAMOXIFEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038068866     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 2001.
2. Woodhouse, E. C., Chuaqui, R. F., and Liotta, L. A. General mechanism of metastasis. Cancer (Phila.), 80: 1529-1537, 1997.
3. Hulka, B. S., Liu, E. T., and Lininger, R. A. Steroid hormones and risk of breast cancer. Cancer (Phila.), 74: 1111-1124, 1994.
4. Lindberg, R. A., and Hunter, T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol. Cell. Biol., 10: 6316-6324, 1990.
5. Zantek, N. D., Azimi, M., Fedor-Chaiken, M., Wang, B., Brackenbury, R., and Kinch, M. S. E-cadherin regulates the function of me EphA2 receptor tyrosine kinase. Cell Growth Differ., 10: 629-638, 1999.
6. Zantek, N. D., Walker-Daniels, J., Stewart, J., Hansen, R. K., Robinson, D., Miao, H., Wang, B., Kung, H. J., Bissell, M. J., and Kinch, M. S. MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin. Cancer Res., 7: 3640-3648, 2001.
7. Miao, H., Bumett, E., Kinch, M., Simon. E., and Wang, B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol., 2: 62-69, 2000.
8. Zelinski, D. P., Zantek, N. D., Stewart, J. C., Irizarry, A. R. and Kinch, M. S. EphA2 overexpression causes lumorigenesis of mammary epithelial cells. Cancer Res., 61: 2301-2306, 2001.
9. Carles-Kinch, K., Kilpatrick, K. E., Stewart, J. C., and Kinch, M. S. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res., 62: 2840-2847, 2002.
10. Hess, A. R., Seftor, E. A., Gardner, L. M., Carles-Kinch, K., Schneider, G. B., Seftor, R. E., Kinch, M. S., and Hendrix, M. J. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res., 61: 3250-3255, 2001.
11. Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., and Pasquale, E. B. The ephrin-A1 ligand and its receptor. EphA2, are expressed during tumor neovascularization. Oncogene, 19: 6043-6052, 2000.
12. Zelinski, D. P., Zantek, N. D., and Walker-Daniels, J., Peters, M. A., Taparowsky, E., J., and Kinch, M. S. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. J. Cell. Biochem., 85: 714-720, 2002.
13. Andres, A. C. Zuercher, G., Djonov, V., Flueck, M., and Ziemiecke, A. Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland. Int. J. Cancer, 63: 288-296, 1995.
14. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., and Sledge, G. W. Constitutive activation of NF-κB during progression of breast cancer to hormoneindependent growth. Mol. Cell. Biol. 17: 3629-3639, 1997.
15. Price, J. E. Metastasis from human breast cancer cell lines. Breast Cancer Res. Treat., 39: 93-102, 1996.
16. Katzenellenhogen, B. S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod., 54: 287-293, 1996.
17. MacGregor, J. I., and Jordan, V. C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev., 50: 151-196, 1998.
18. Dickson, R. B., and Lippman, M. E. Growth factors in breast cancer. Endocr. Rev., 16: 559-589, 1995.
19. Katzenellenbogen, B. S., Choi, I. Delage-Mourroux, R., Ediger, T. R., Martini, P. G., Montano, M., Sun, J., Weis, K., and Katzenellenbogen, J. A. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol., 74: 279-285, 2000.
20. Zajchowski, D., Sager, R., and Webster, L. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing recombinant estrogen receptor. Cancer Res., 53: 5004-5011, 1993.
21. Rochefort, H. Oestrogen- and anti-oestrogen-regulated genes in human breast cancer. CIBA Found. Symp., 191: 254-265, 1995.